Using market-research information builds comprehension of the communities OneOncology treats, which allows us to implement effective technologies for value-based care, said Robin Shah, chief commercial officer of OneOncology.
Using market-research information builds comprehension of the communities OneOncology treats, which allows us to implement effective technologies for value-based care, said Robin Shah, chief commercial officer of OneOncology.
Transcript
With a shift toward value-based care, there’s an emphasis placed on the standardization of care, but this can be hard for community oncologists who see a range of different types of cancer. Does the technology OneOncology uses help address this?
With the work that we’re doing with our physician leadership at OneCouncil, we’re building a platform so that we can, 1, understand what technology is needed to be successful in a value-based program and then how do you deploy that technology. So, the way we think about it is you need to understand the parameters of what program you’re going into, and then build software and solutions, operational, that can help a practice succeed in a value-based program. So, we’ve built an entire clinical and operational team thinking about that together.
Does artificial intelligence or machine learning play a part, or will it play a part in the future, in helping drive appropriate care?
We’re in the very early stages of using machine learning for driving value in alternative models, but we are starting some of that. One of the things that we’re learning is that with the wealth of data, you can start to learn where you can make process improvement changes, but this starts with building the data asset. So, with all the work that we’re building towards building OneAnalytics, we think in the future as we really go into risk-based contracts across our entire network, we’ll be able to use some type of machine learning with a partner like Flatiron or others.
How is this technology helping community oncologists stay competitive in a growing consolidating market?
So, as we think about software in the community space, a lot of what we’re adding to our platform is market-research information. So, not only do we think about software and data to help our practices be better, but how do we learn more about the communities that we’re in, how do we learn about the places where cancer patients are actually coming from, and how do our practices collaborate and build models where those patients can understand what services are provided within our communities. So, with the competitive landscape across the entire country, it’s important to look at the entire community and not just the technology that we’re using within our clinics.
The Challenge of Addressing Drug Spend to Drive Down Total Cost of Care in EOM
October 27th 2024Stuart Staggs, vice president of transformation and shared services at McKesson, explained that oncology practices in the Enhancing Oncology Model (EOM) have a tough job driving down costs when drug costs make up a larger portion of the total cost of care.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More